Search
AIM ImmunoTech Inc
AIMAdd to Watchlist
0.250USD
-0.008-3.10%
Market hours （ET）Quotes delayed by 15 min
768.24KMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-3.10%
5 Days
-55.36%
1 Month
-56.78%
6 Months
-82.25%
Year to Date
-77.85%
1 Year
0.00%
TradingKey Stock Score of AIM ImmunoTech Inc
Currency: USD Updated: 2026-05-14Key Insights
AIM ImmunoTech Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 130 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AIM ImmunoTech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
AIM ImmunoTech Inc Highlights
StrengthsRisks
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Growing
The company is in a growing phase, with the latest annual income totaling USD 88.00K.
Overvalued
The company’s latest PE is -0.03, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 105.74K shares, decreasing 41.27% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+3590.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
AIM ImmunoTech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
AIM ImmunoTech Inc Info
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Ticker SymbolAIM
CompanyAIM ImmunoTech Inc
CEOEquels (Thomas K)
Websitehttps://aimimmuno.com/
Related Instruments
+0.21%
-2.26%
-0.94%
+0.18%
-0.85%
-1.71%
-2.77%
-1.84%
-2.89%
-1.61%
-0.74%
-2.05%
+0.16%
-3.05%
+1.65%
0.00%
-2.25%
-0.12%
-2.08%
+0.99%Popular Instruments
101.390
+2.527 (+2.56%)
302.030
+3.820 (+1.28%)
227.400
-8.340 (-3.54%)
4543.760
-106.470 (-2.29%)
480.010
-9.140 (-1.87%)
1399.190
+16.470 (+1.19%)
738.000
-38.010 (-4.90%)
397.070
-4.000 (-1.00%)
79139.760
-2242.280 (-2.75%)
425.280
-18.020 (-4.07%)
